In a case report of a patient with mutated CSF3R-T618I, hydroxyurea-refractory aCML, the use of ruxolitinib led to a reduction in constitutional symptoms, leucocytosis, and the spleen size, as well as an improvement in anemia and thrombocytopenia [71]. Here, CSF3R is linked to atypical chronic myeloid leukemia, BCR-ABL1 negative.